Navigation Links
Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention

BEVERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inotek Pharmaceuticals Corporation announced today the presentation of positive Phase 2 clinical data demonstrating the safety of INO-1001 as well as the potential for INO-1001 as a preventative agent for cardiac reperfusion injury. The study was conducted in subjects with acute ST-elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The presentation was made in a poster session at the American College of Cardiology (ACC) 56th Annual Scientific Session in New Orleans, Louisiana. INO-1001 is an inhibitor of poly(ADP-Ribose) polymerase (PARP), a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and is being studied as a treatment for certain acute cardiovascular conditions and cancer. Additionally, PARP inhibition shows promise in inflammatory disorders. PARP's role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1).

"Whereas advances in pharmacologic and mechanical reperfusion therapy have improved the outcomes of patients with STEMI, reperfusion injury, which is associated with severe damage to the cardiac tissue, is a significant complication that has no current safe and effective treatment options," commented Dr. Andrew Salzman, Inotek's President and CEO. "These Phase 2 data provide further support for our PARP inhibitor program in cardiovascular disease. These results combined with existing preclinical data suggest that INO-1001 produces significant PARP inhibition and has the potential to protect cardiac tissue from damage."

Researchers from the Brigham and Women's TIMI Study Group and Inotek Pharmaceuticals reported that plasma from patients treated with INO-1001 suppressed ex vivo PARP activation. This effect was observed up to 24 hours following drug admi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 ... has announced the addition of the "Investigation ... to their offering. Developed by Pharmacia ... prostaglandin receptor agonist which effectively reduces intraocular pressure. ... FDA, latanoprost (under the trade name of Xalatan) ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... , Joint research by Prof. Kim ... , Published in ,Stem Cells Translational Medicine, (IF ... multiple IV administration of Adipose-derived MSC , Increase ... , Commercialization within 5 years expected ... adult mesenchymal stem cells (MSCs) may extend healthy life ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2
(Date:8/28/2015)... Tempe, AZ (PRWEB) , ... August 29, 2015 , ... ... to reinvent higher learning and the student experience as part of the EDUCAUSE - ... Melinda Gates Foundation . , This is the third Breakthrough Models Incubator ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... An ... that local pizza maker Paul LaRocco has gone through to open a pizzeria in ... and permitting process tends to take several months, but the current process, having already ...
(Date:8/28/2015)... MA (PRWEB) , ... August 28, 2015 , ... The ... benefitting the renowned Brain Aneurysm Foundation has added yet another accolade to its cadre ... Rahm Emanuel. , “With the help of the medical community and the ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices, ... Device Model, Cisco Nexus 5000 Series, HP ProLiant Gen9, EMC VNX Series , ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Dr. Gregory ... such as radiating pain resulting in shoulder pain, hip pain, neck pain, ... in Civil Engineering from the University of Illinois, and then went on to earn ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3
... Oct. 29 Irvine Pharmaceutical Services,Inc., announced today that ... current and future industry demands, the company has promoted ... and added,to its staff Chief Operating Officer Greg McParland. ... growth as it gears up to launch its new,subsidiary, ...
... 29 Nu Skin Enterprises,Inc. (NYSE: NUS ... the,quarter of $310.3 million, a 7 percent improvement ... a 26 percent improvement over the,same quarter of ... 2,percent by foreign currency fluctuations and earnings per ...
... acquire US rights in tesamorelin, a Phase III compound ... HIV patients with lipodystrophy -- ... royalties on net sales in the US -- Merck KGaA, ... make equity investment in Theratechnologies -- EMD ...
... Use IPL to Clear Acne Blemishes, COSTA ... the CLARO acne-clearing device received marketing clearance by,the ... of mild to moderate,inflammatory acne. CLARO, the first ... treatment of acne, will be available by prescription,January ...
... of crafting smiles for Californians, Ron Greenspan, DDS, has been selected for ... the Washington, D.C. based U.S. Local Business Association (USLBA). , ... San ... smiles for Californians, Ron Greenspan, DDS, has been selected for the 2008 ...
... and increasing concerns for oral hygiene are considered the main factors contributing ... projected to reach $12.7 billion by the year 2012. , ... San ... one of the most dynamic segments of the oral care market. The ...
Cached Medicine News:Health News:Irvine Pharmaceutical Services Enhances Staff, Prepares for Innovative Expansion 2Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 2Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 3Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 4Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 5Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 6Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 7Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 8Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 9Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 10Health News:Nu Skin Enterprises Reports Third-Quarter 2008 Results 11Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 2Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 3Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 4Health News:EMD Serono and Theratechnologies Announce Collaboration and Licensing Agreement for Tesamorelin in the United States 5Health News:CLARO Receives FDA-Clearance for Treatment of Acne 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 2Health News:Dr. Ron Greenspan has Been Selected for the 2008 Best of San Diego Award in the Orthodontists Category by the U.S. Local Business Association 3Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 2Health News:Global Toothpaste Market to Reach $12.7 Billion by 2012, According to a New Report by Global Industry Analysts, Inc. 3
... III DLE (Drug List Editor) Multi-Channel Infusion ... infusion technology. The instrument combines three independent ... versatility in an unparalleled small size. Now ... III Infusion System simplifies the delivery of ...
... The Gemini Family of infusion ... with a collective series of ... product line offers a wide ... IV sets, each featuring the ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Medicine Products: